New insights in the pathogenesis of high-altitude pulmonary edema

Progress in Cardiovascular Diseases

Volumn 52, Issue 6, 2010, Pages 485-492

  Scherrer, Urs ^a   Rexhaj, Emrush ^a   Jayet, Pierre Yves ^a   Allemann, Yves ^a   Sartori, Claudio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ENDOTHELIN 1; NITRIC OXIDE; SODIUM; TADALAFIL;

ALTITUDE DISEASE; ARTICLE; HUMAN; HYPOXIA; HYPOXIC LUNG VASOCONSTRICTION; LUNG ALVEOLUS EPITHELIUM; LUNG BLOOD VESSEL; LUNG CLEARANCE; LUNG EDEMA; LUNG ENDOTHELIUM; LUNG FLUID; NONHUMAN; PATENT FORAMEN OVALE; PATHOGENESIS; PULMONARY HYPERTENSION; SODIUM TRANSPORT;

ALTITUDE; ALTITUDE SICKNESS; ENDOTHELIN-1; FORAMEN OVALE, PATENT; HUMANS; HYPERTENSION, PULMONARY; MOUNTAINEERING; NITRIC OXIDE; PULMONARY ALVEOLI; PULMONARY CIRCULATION; PULMONARY EDEMA; RESPIRATORY MUCOSA; RISK FACTORS; SODIUM; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION;

EID: 77952147405     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.02.004     Document Type: Article

References (53)

1. Staub N.C. Pulmonary edema. Physiol Rev 1974, 54:678-811.
2. Sartori C., Allemann Y., Scherrer U. Pathogenesis of pulmonary edema: learning from high-altitude pulmonary edema. Respir Physiol Neurobiol 2007, 159:338-349.
3. Cremona G., Asnaghi R., Baderna P., et al. Pulmonary extravascular fluid accumulation in recreational climbers: a prospective study. Lancet 2002, 359:303-309.
4. Scherrer U., Sartori C., Lepori M., et al. High-altitude pulmonary edema: from exaggerated pulmonary hypertension to a defect in transepithelial sodium transport. Adv Exp Med Biol 1999, 474:93-107.
5. Hultgren H.N. High-altitude pulmonary edema: current concepts. Ann Rev Med 1996, 47:267-284.
6. Schoene R.B. Fatal high altitude pulmonary edema associated with absence of the left pulmonary artery. High Alt Med Biol 2001, 2:405-406.
7. Rios B., Driscoll D.J., McNamara D.G. High-altitude pulmonary edema with absent right pulmonary artery. Pediatrics 1985, 75:314-317.
8. Durmowicz A.G. Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes. Pediatrics 2001, 108:443-447.
9. Scherrer U., Turini P., Thalmann S., et al. Pulmonary hypertension in high-altitude dwellers: novel mechanisms, unsuspected predisposing factors. Adv Exp Med Biol 2006, 588:277-291.
10. Hackett P.H., Roach R.C., Hartig G.S., et al. The effect of vasodilatators on pulmonary hemodynamics in high-altitude pulmonary edema-a comparison. Int J Sports Med 1992, 13:68-74.
11. Bärtsch P., Maggiorini M., Ritter M., et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991, 325:1284-1289.
12. Maggiorini M., Brunner-La Rocca H.P., Peth S., et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006, 145:497-506.
13. Scherrer U., Vollenweider L., Delabays A., et al. Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 1996, 334:624-629.
14. Maggiorini M., Melot C., Pierre S., et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 2001, 103:2078-2083.
15. Zhao Y., Packer C.S., Rhoades R.A. Pulmonary vein contracts in response to hypoxia. Am J Physiol 1993, 265:L87-L92.
16. Mitzner W., Sylvester J.T. Hypoxic vasoconstriction and fluid filtration in pig lungs. J Appl Physiol 1981, 51:1065-1071.
17. Swenson E.R., Maggiorini M., Mongovin S., et al. Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. JAMA 2002, 287:2228-2235.
18. Duplain H., Sartori C., Lepori M., et al. Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 2000, 162:221-224.
19. Blitzer M.L., Loh E., Roddy M.A., et al. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 1996, 28:591-596.
20. Frostell C.G., Fratacci M.D., Wain J.C., et al. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991, 83:2038-2047.
21. Ahsan A., Charu R., Pasha M.A., et al. eNOS allelic variants at the same locus associate with HAPE and adaptation. Thorax 2004, 59:1000-1002.
22. Droma Y., Hanaoka M., Ota M., et al. Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 2002, 106:826-830.
23. Ahsan A., Norboo T., Baig M.A., et al. Simultaneous selection of the wild-type genotypes of the G894T and 4B/ 4A polymorphisms of NOS3 associate with high-altitude adaptation. Ann Hum Genet 2005, 69:260-267.
24. Hoshikawa Y., Ono S., Suzuki S., et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001, 90:1299-1306.
25. Bowers R., Cool C., Murphy R.C., et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004, 169:764-769.
26. Settergren G., Angdin M., Astudillo R., et al. Decreased pulmonary vascular resistance during nasal breathing: modulation by endogenous nitric oxide from the paranasal sinuses. Acta Physiol Scand 1998, 163:235-239.
27. Sartori C., Lepori M., Busch T., et al. Exhaled nitric oxide does not provide a marker of vascular endothelial function in healthy humans. Am J Respir Crit Care Med 1999, 160:879-882.
28. Busch T., Bartsch P., Pappert D., et al. Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J RespirCrit Care Med 2001, 163:368-373.
29. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
30. Goerre S., Wenk M., Bärtsch P., et al. Endothelin-1 in pulmonary hypertension associated with high altitude exposure. Circulation 1995, 91:359-364.
31. Modesti P.A., Vanni S., Morabito M., et al. Role of endothelin-1 in exposure to high altitude: acute mountain sickness and endothelin-1 (ACME-1) study. Circulation 2006, 114:1410-1416.
32. Sartori C., Vollenweider L., Loffler B.M., et al. Exaggerated endothelin release in high-altitude pulmonary edema. Circulation 1999, 99:2665-2668.
33. Kourembanas S., McQuillan L.P., Leung G.K., et al. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993, 92:99-104.
34. Dauber I.M., Weil J.V. Lung injury edema in dogs: influence of sympathetic ablation. J Clin Invest 1983, 72:1977-1986.
35. Duplain H., Vollenweider L., Delabays A., et al. Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high altitude pulmonary edema. Circulation 1999, 99:1713-1718.
36. Sartori C., Lepori M., Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 2005, 106:209-220.
37. Scherrer U., Vollenweider P., Randin D., et al. Suppression of insulin induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 1993, 88:388-394.
38. Randin D., Vollenweider P., Tappy L., et al. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 1995, 332:1733-1737.
39. Hackett P.H., Roach R.C., Schoene R.B., et al. Abnormal control of ventilation in high-altitude pulmonary edema. J Appl Physiol 1988, 64:1268-1272.
40. Wagner P.D., Sutton J.R., Reeves J.T., et al. Pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol 1987, 63:2348-2359.
41. Levine B.D., Grayburn P.A., Voyles W.F., et al. Intracardiac shunting across a patent foramen ovale may exacerbate hypoxemia in high-altitude pulmonary edema. Ann Intern Med 1991, 114:569-570.
42. Allemann Y., Hutter D., Lipp E., et al. Patent foramen ovale and high-altitude pulmonary edema. JAMA 2006, 296:2954-2958.
43. Torti S.R., Billinger M., Schwerzmann M., et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J 2004, 25:1014-1020.
44. Kerut E.K., Norfleet W.T., Plotnick G.D., et al. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001, 38:613-623.
45. Benumof J.L., Pirlo A.F., Johanson I., et al. Interaction of PVO2 with PAO2 on hypoxic pulmonary vasoconstriction. J Appl Physiol 1981, 51:871-874.
46. Sartori C., Allemann Y., Trueb L., et al. Augmented vasoreactivity in adult life associated with perinatal vascular insult. Lancet 1999, 353:2205-2207.
47. Sartori C., Allemann Y., Trueb L., et al. Exaggerated pulmonary hypertension is not sufficient to trigger high-altitude pulmonary oedema in humans. Schweiz Med Wochenschr 2000, 130:385-389.
48. Sartori C., Allemann Y., Duplain H., et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002, 346:1631-1636.
49. Egli M., Duplain H., Lepori M., et al. Defective respiratory amiloride-sensitive sodium transport predisposes to pulmonary oedema and delays its resolution in mice. J Physiol 2004, 560:857-865.
50. Sartori C., Duplain H., Lepori M., et al. High altitude impairs nasal transepithelial sodium transport in HAPE-prone subjects. Eur Respir J 2004, 23:916-920.
51. Sakuma T., Folkesson H., Suzuki S., et al. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med 1997, 155:506-512.
52. Perkins G.D., McAuley D.F., Thickett D.R., et al. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006, 173:281-287.
53. Licker M., Tschopp J.M., Robert J., et al. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 2008, 133:845-852.